KR20210041035A - 알츠하이머병의 판정약 및 판정 방법 - Google Patents
알츠하이머병의 판정약 및 판정 방법 Download PDFInfo
- Publication number
- KR20210041035A KR20210041035A KR1020217006577A KR20217006577A KR20210041035A KR 20210041035 A KR20210041035 A KR 20210041035A KR 1020217006577 A KR1020217006577 A KR 1020217006577A KR 20217006577 A KR20217006577 A KR 20217006577A KR 20210041035 A KR20210041035 A KR 20210041035A
- Authority
- KR
- South Korea
- Prior art keywords
- disease
- alzheimer
- gly
- leu
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2018-148924 | 2018-08-07 | ||
| JP2018148924 | 2018-08-07 | ||
| PCT/JP2019/030904 WO2020032027A1 (ja) | 2018-08-07 | 2019-08-06 | アルツハイマー病の判定薬および判定方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210041035A true KR20210041035A (ko) | 2021-04-14 |
Family
ID=69413505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217006577A Abandoned KR20210041035A (ko) | 2018-08-07 | 2019-08-06 | 알츠하이머병의 판정약 및 판정 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12000844B2 (https=) |
| EP (1) | EP3835424A4 (https=) |
| JP (2) | JP7470041B2 (https=) |
| KR (1) | KR20210041035A (https=) |
| CN (1) | CN112567039B (https=) |
| AU (1) | AU2019318888A1 (https=) |
| CA (1) | CA3108440A1 (https=) |
| MX (1) | MX2021001507A (https=) |
| TW (1) | TW202035438A (https=) |
| WO (1) | WO2020032027A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115066610A (zh) * | 2020-02-05 | 2022-09-16 | 住友制药株式会社 | 用于tau病变和痴呆相关疾病的确定试剂和确定方法 |
| AU2021218735A1 (en) * | 2020-02-13 | 2022-09-01 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
| CN117447590B (zh) * | 2023-11-23 | 2024-04-26 | 中国检验检疫科学研究院 | 一种抗赤羽病病毒单克隆抗体、分泌抗赤羽病病毒单克隆抗体的杂交瘤细胞及其应用 |
| CN121272033A (zh) * | 2025-08-21 | 2026-01-06 | 广东益尔生物技术有限公司 | 一种Circ-sAPPα及sAPPα-199aa作为阿尔茨海默症的检测标志物的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012091138A1 (ja) | 2010-12-28 | 2012-07-05 | 大日本住友製薬株式会社 | アルツハイマー病の診断薬及び診断方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| SG191620A1 (en) | 2008-07-08 | 2013-07-31 | Sumitomo Bakelite Co | Positive photosensitive resin composition, cured film, protecting film, insulating film, and semiconductor device and display device using the same |
| WO2010048497A1 (en) * | 2008-10-24 | 2010-04-29 | Genizon Biosciences Inc. | Genetic profile of the markers associated with alzheimer's disease |
| CN109924024B (zh) | 2013-03-05 | 2021-11-23 | 现特技术有限公司 | 光子调制管理系统 |
| CN115066610A (zh) * | 2020-02-05 | 2022-09-16 | 住友制药株式会社 | 用于tau病变和痴呆相关疾病的确定试剂和确定方法 |
-
2019
- 2019-08-06 AU AU2019318888A patent/AU2019318888A1/en not_active Abandoned
- 2019-08-06 MX MX2021001507A patent/MX2021001507A/es unknown
- 2019-08-06 TW TW108127965A patent/TW202035438A/zh unknown
- 2019-08-06 KR KR1020217006577A patent/KR20210041035A/ko not_active Abandoned
- 2019-08-06 CA CA3108440A patent/CA3108440A1/en active Pending
- 2019-08-06 WO PCT/JP2019/030904 patent/WO2020032027A1/ja not_active Ceased
- 2019-08-06 US US17/265,805 patent/US12000844B2/en active Active
- 2019-08-06 CN CN201980052567.4A patent/CN112567039B/zh active Active
- 2019-08-06 EP EP19846675.7A patent/EP3835424A4/en not_active Withdrawn
- 2019-08-06 JP JP2020535789A patent/JP7470041B2/ja active Active
-
2024
- 2024-02-01 JP JP2024014251A patent/JP7654126B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012091138A1 (ja) | 2010-12-28 | 2012-07-05 | 大日本住友製薬株式会社 | アルツハイマー病の診断薬及び診断方法 |
Non-Patent Citations (1)
| Title |
|---|
| Exp Gerontol. (2000) 35: 851-64 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7654126B2 (ja) | 2025-03-31 |
| EP3835424A1 (en) | 2021-06-16 |
| EP3835424A4 (en) | 2022-05-04 |
| US20210165002A1 (en) | 2021-06-03 |
| CN112567039A (zh) | 2021-03-26 |
| CN112567039B (zh) | 2024-11-26 |
| CA3108440A1 (en) | 2020-02-13 |
| MX2021001507A (es) | 2021-04-28 |
| JP2024054181A (ja) | 2024-04-16 |
| JP7470041B2 (ja) | 2024-04-17 |
| AU2019318888A1 (en) | 2021-03-18 |
| WO2020032027A1 (ja) | 2020-02-13 |
| US12000844B2 (en) | 2024-06-04 |
| JPWO2020032027A1 (ja) | 2021-09-09 |
| TW202035438A (zh) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7654126B2 (ja) | アルツハイマー病の判定薬および判定方法 | |
| KR101883515B1 (ko) | 알츠하이머 병의 진단약 및 진단 방법 | |
| TWI853145B (zh) | Tau蛋白病變及失智症相關疾病之判定藥及判定方法 | |
| CN101743473A (zh) | 移植物抗宿主疾病的检查及治疗方法 | |
| WO2011005628A1 (en) | Detection of neurodegenerative disease | |
| EP2817632B1 (en) | New dual biomarker of neurodegeneration and of neuroregeneration | |
| HK40048565A (en) | Diagnostic drug and diagnostic method for alzheimer's disease | |
| HK40077327A (en) | Determination agent and determination method for tauopathy and dementia-related diseases | |
| JP2023132247A (ja) | シヌクレイノパシー検出用バイオマーカー及びその利用 | |
| HK1187404B (en) | Diagnostic drug and diagnostic method for alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PC1902 | Submission of document of abandonment before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1902 |